Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.

Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F.

Oncotarget. 2017 Jul 31;8(39):66019-66032. doi: 10.18632/oncotarget.19732. eCollection 2017 Sep 12.

2.

MARCKS protein overexpression in inflammatory breast cancer.

Manai M, Thomassin-Piana J, Gamoudi A, Finetti P, Lopez M, Eghozzi R, Ayadi S, Lamine OB, Manai M, Rahal K, Charafe-Jauffret E, Jacquemier J, Viens P, Birnbaum D, Boussen H, Chaffanet M, Bertucci F.

Oncotarget. 2017 Jan 24;8(4):6246-6257. doi: 10.18632/oncotarget.14057.

3.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

4.

Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M.

PLoS One. 2014 Jan 9;9(1):e81843. doi: 10.1371/journal.pone.0081843. eCollection 2014.

5.

Cytokeratin 7 as a predictive factor for response to concommitant radiochemotherapy for locally advanced cervical cancer: a preliminary study.

Lambaudie E, Chereau E, Pouget N, Thomassin J, Minsat M, Charafe-Jauffret E, Jacquemier J, Houvenaeghel G.

Anticancer Res. 2014 Jan;34(1):177-81.

PMID:
24403459
6.

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.

Cancer Res. 2013 Dec 15;73(24):7290-300. doi: 10.1158/0008-5472.CAN-12-4704. Epub 2013 Oct 18.

7.

Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.

Franchet C, Filleron T, Cayre A, Mounié E, Penault-Llorca F, Jacquemier J, Macgrogan G, Arnould L, Lacroix-Triki M.

Histopathology. 2014 Jan;64(2):274-83. doi: 10.1111/his.12247. Epub 2013 Oct 1.

PMID:
24117939
8.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

9.

Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.

Hassanein M, Huiart L, Bourdon V, Rabayrol L, Geneix J, Nogues C, Peyrat JP, Gesta P, Meynard P, Dreyfus H, Petrot D, Lidereau R, Noguchi T, Eisinger F, Extra JM, Viens P, Jacquemier J, Sobol H.

Pathobiology. 2013;80(5):219-27. doi: 10.1159/000339432. Epub 2013 Apr 23.

10.

Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets.

Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J, Houvenaeghel G, Bertucci F, Birnbaum D, Olive D.

J Immunol. 2013 Mar 1;190(5):2424-36. doi: 10.4049/jimmunol.1200140. Epub 2013 Jan 28.

11.

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, Birnbaum D, Penault-Llorca F.

Ann Oncol. 2013 Mar;24(3):625-32. doi: 10.1093/annonc/mds510. Epub 2012 Nov 1.

PMID:
23117074
12.

Breast metastasis of a squamous cell carcinoma of the uterine cervix mimicking inflammatory breast cancer.

Sabatier R, Roussin C, Riviere JP, Jalaguier A, Jacquemier J, Bertucci F.

Case Rep Oncol. 2012 May;5(2):464-70. doi: 10.1159/000342255. Epub 2012 Aug 29.

13.

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP.

Breast Cancer Res Treat. 2012 Apr;132(3):895-915. doi: 10.1007/s10549-011-1837-z. Epub 2011 Nov 3. Review.

14.

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.

Jacquemier J, Boher JM, Roche H, Esterni B, Serin D, Kerbrat P, Andre F, Finetti P, Charafe-Jauffret E, Martin AL, Campone M, Viens P, Birnbaum D, Penault-Llorca F, Bertucci F.

Breast Cancer Res. 2011;13(6):R109. doi: 10.1186/bcr3051. Epub 2011 Nov 1.

15.

Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: nomogram validation and comparison with other models.

Houvenaeghel G, Bannier M, Nos C, Giard S, Mignotte H, Jacquemier J, Martino M, Esterni B, Belichard C, Classe JM, Tunon de Lara C, Cohen M, Payan R, Blanchot J, Rouanet P, Penault-Llorca F, Bonnier P, Fournet S, Agostini A, Marchal F, Garbay JR.

Breast. 2012 Apr;21(2):204-9. doi: 10.1016/j.breast.2011.09.013. Epub 2011 Oct 19.

16.

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D.

J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.

17.

Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature.

Cauvin C, Moureau-Zabotto L, Chetaille B, Hilgers W, Denoux Y, Jacquemier J, Guiramand J, Sarran A, Bertucci F.

BMC Cancer. 2011 Jul 29;11:323. doi: 10.1186/1471-2407-11-323. Review.

18.

Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients.

Le Frère-Belda MA, Bats AS, Gillaizeau F, Poulet B, Clough KB, Nos C, Peoc'h M, Seffert P, Bouteille C, Leroux A, Guillemin F, Blanc-Fournier C, Crouet H, Arnould L, Cuisenier J, Penault-Llorca F, Gimbergues P, Jacquemier J, Houvenaeghel G, Chatellier G, Lécuru F.

Int J Cancer. 2012 May 15;130(10):2377-86. doi: 10.1002/ijc.26291. Epub 2011 Aug 27.

19.

Kinome expression profiling and prognosis of basal breast cancers.

Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2011 Jul 21;10:86. doi: 10.1186/1476-4598-10-86.

20.

Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer.

Sabatier R, Finetti P, Cervera N, Tallet A, Benchalal M, Houvenaeghel G, Jacquemier J, Birnbaum D, Bertucci F.

Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):199-209.

PMID:
21737613
21.

A seven-gene prognostic model for platinum-treated ovarian carcinomas.

Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E, Viens P, Birnbaum D, Bertucci F.

Br J Cancer. 2011 Jul 12;105(2):304-11. doi: 10.1038/bjc.2011.219. Epub 2011 Jun 7.

22.

Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.

Gilabert M, Bertucci F, Esterni B, Madroszyk A, Tarpin C, Jacquemier J, Extra JM, Viens P, Gonçalves A.

Anticancer Res. 2011 Mar;31(3):1079-86.

PMID:
21498742
23.

Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome.

Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F, Birnbaum D, Viens P, Gonçalves A, Extra JM.

Eur J Cancer. 2011 Jul;47(10):1537-45. doi: 10.1016/j.ejca.2011.02.002. Epub 2011 Mar 8.

PMID:
21392964
24.

High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.

Bekhouche I, Finetti P, Adelaïde J, Ferrari A, Tarpin C, Charafe-Jauffret E, Charpin C, Houvenaeghel G, Jacquemier J, Bidaut G, Birnbaum D, Viens P, Chaffanet M, Bertucci F.

PLoS One. 2011 Feb 9;6(2):e16950. doi: 10.1371/journal.pone.0016950.

25.

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C.

EMBO Mol Med. 2011 Mar;3(3):153-66. doi: 10.1002/emmm.201100121. Epub 2011 Feb 15. Erratum in: EMBO Mol Med. 2011 Mar;3(3). doi:10.1002/emmm.201000121.

26.

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, Van den Eynde B, Birnbaum D, Olive D, Xerri L.

Int J Cancer. 2012 Jan 1;130(1):96-104. doi: 10.1002/ijc.25979.

27.

Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions.

Cserni G, Amendoeira I, Bianchi S, Chmielik E, Degaetano J, Faverly D, Figueiredo P, Foschini MP, Grabau D, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Penuela JM, Quinn C, Regitnig P, Reiner-Concin A, Sapino A, van Diest PJ, Varga Z, Vezzosi V, Wesseling J, Zolota V, Zozaya E, Wells CA.

Eur J Cancer. 2011 Apr;47(6):887-94. doi: 10.1016/j.ejca.2010.11.011. Epub 2010 Dec 16.

PMID:
21168328
28.

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS.

Mod Pathol. 2011 Feb;24(2):157-67. doi: 10.1038/modpathol.2010.200. Epub 2010 Nov 12. Review.

29.

[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, Bellocq JP, Matthieu MC, Grogan GM, Treilleux I, Ettore F, Laberge-Le Couteulx S, Sigal B, Couturier J, Lacroix-Triki M, Antoine M, Balaton A, Baranzelli MC, Becette V, Blanc-Fournier C, Bibeau F, Brabencova E, Croce S, Fridman V, Génin P, Ghnassia JP, Jacquemier J, Poulet B, Roger P, Sagan C, Tas P, Trassard M, Verriele V, Arnould L; GEFPICS.

Ann Pathol. 2010 Oct;30(5):357-73. doi: 10.1016/j.annpat.2010.07.001. Epub 2010 Oct 16. French.

PMID:
21055523
30.

Genome profiling of ERBB2-amplified breast cancers.

Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.

BMC Cancer. 2010 Oct 8;10:539. doi: 10.1186/1471-2407-10-539.

31.

Breast cancer prognostic classification in the molecular era: the role of histological grade.

Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO.

Breast Cancer Res. 2010;12(4):207. doi: 10.1186/bcr2607. Epub 2010 Jul 30. Review.

32.

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A, Treilleux I, Finetti P, Esterni B, Extra JM, Geneve J, Hermitte F, Chabannon C, Jacquemier J, Martin AL, Longy M, Maraninchi D, Fert V, Birnbaum D, Viens P.

Breast Cancer Res Treat. 2011 Jun;127(2):363-73. doi: 10.1007/s10549-010-1003-z. Epub 2010 Jun 29.

PMID:
20585850
33.

Sonographic appearance of a metastasis to the breast from a cerebellar medulloblastoma.

Ternier F, Hadjaj D, Jacquemier J.

J Clin Ultrasound. 2010 Jul;38(6):335-7. doi: 10.1002/jcu.20698.

PMID:
20544872
34.

A gene expression signature identifies two prognostic subgroups of basal breast cancer.

Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Breast Cancer Res Treat. 2011 Apr;126(2):407-20. doi: 10.1007/s10549-010-0897-9. Epub 2010 May 21.

35.

[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].

Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L.

Bull Cancer. 2010 Mar;97(3):357-63. doi: 10.1684/bdc.2010.1062. French.

36.

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS.

Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.

37.

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.

Gonçalves A, Deblock M, Esterni B, Tarpin C, Bertucci F, Gilabert M, Charafe-Jauffret E, Jacquemier J, Houvenaeghel G, Extra JM, Viens P.

Anticancer Drugs. 2009 Nov;20(10):946-52. doi: 10.1097/CAD.0b013e328331178f.

PMID:
19741502
38.

[Diagnostic pitfalls in mammary pathology. Case 5. Secretory carcinoma].

Jacquemier J.

Ann Pathol. 2009 Jun;29(3):211-5. doi: 10.1016/j.annpat.2009.02.010. Epub 2009 Jun 21. French. No abstract available.

PMID:
19619828
39.

Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.

Perez-Ellis C, Goncalves A, Jacquemier J, Marty M, Girre V, Roché H, Brain E, Moatti JP, Viens P, Le Corroller-Soriano AG.

Am J Clin Oncol. 2009 Oct;32(5):492-8.

PMID:
19487912
40.

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.

Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D.

Breast Cancer Res. 2009;11(2):R23. doi: 10.1186/bcr2249. Epub 2009 Apr 30.

41.

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H.

J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.

PMID:
19380452
42.

18 Fluoro-2deoxy-d-glucose-positron emission tomography and locally advanced cervical cancer.

Motton S, De Lapparent T, Brenot-Rossi I, Buttarelli M, Al Nakib M, Jacquemier J, Tallet A, Houvenaeghel G.

Int J Gynecol Cancer. 2009 Jan;19(1):8-12. doi: 10.1111/IGJ.0b013e318197f276.

PMID:
19258934
43.

Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy.

Menard JP, Extra JM, Jacquemier J, Buttarelli M, Lambaudie E, Bannier M, Brenot Rossi I, Houvenaeghel G.

Eur J Surg Oncol. 2009 Sep;35(9):916-20. doi: 10.1016/j.ejso.2008.11.002. Epub 2009 Jan 20.

PMID:
19157769
44.

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.

45.

[Margin status in invasive breast cancer].

Houvenaeghel G, Lambaudie E, Buttarelli M, Cohen M, Bannier M, Tallet A, Jacquemier J.

Bull Cancer. 2008 Dec;95(12):1161-70. doi: 10.1684/bdc.2008.0766. Review. French.

46.

How different are luminal A and basal breast cancers?

Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D.

Int J Cancer. 2009 Mar 15;124(6):1338-48. doi: 10.1002/ijc.24055.

47.

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis.

Houvenaeghel G, Nos C, Giard S, Mignotte H, Esterni B, Jacquemier J, Buttarelli M, Classe JM, Cohen M, Rouanet P, Penault Llorca F, Bonnier P, Marchal F, Garbay JR, Fraisse J, Martel P, Fondrinier E, Tunon de Lara C, Rodier JF.

Eur J Surg Oncol. 2009 Jul;35(7):690-5. doi: 10.1016/j.ejso.2008.10.003. Epub 2008 Nov 28.

PMID:
19046847
48.

Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients.

Bremer TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP.

Int J Cancer. 2009 Feb 15;124(4):896-904. doi: 10.1002/ijc.24001.

49.

Absence of ESR1 amplification in a series of breast cancers.

Adélaïde J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, Bertucci F, Birnbaum D, Chaffanet M.

Int J Cancer. 2008 Dec 15;123(12):2970-2. doi: 10.1002/ijc.23786. No abstract available.

50.

Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles.

Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC, Bibeau F, Mathieu MC, Treilleux I, Jacquemier J, Ursule L, Martinec A, Wang Q, Bénard J, Puisieux A, Birnbaum D, Theillet C.

Oncogene. 2008 Sep 11;27(40):5359-72. doi: 10.1038/onc.2008.158. Epub 2008 May 19.

Supplemental Content

Loading ...
Support Center